

Amendments to the Claims

The following listing of claims will replace all prior versions, and listings of claims in the application.

1. (Currently Amended) A method of treatment ~~or prevention~~ of metastasis of cancer cells consisting of administering to a patient in need of treatment an effective amount of a composition consisting essentially of an angiotensin, wherein said method treats ~~or prevents~~ metastasis of said cancer cells.
2. (Previously Presented) The method as claimed in claim 1, wherein said cancer cells are derived from at least one of the group consisting of breast, skin, large bowel, prostate, lung, bone, cervix, stomach and rectum.
3. (Previously Presented) The method as claimed in claim 1, wherein said angiotensin is angiotensin-II.
4. (Canceled) The use of an angiotensin in the preparation of a medicament for the prevention or treatment of metastasis of cancer cells.
5. (Previously Presented) The method as claimed in claim 1, wherein said administering is oral, rectal, nasal, topical, vaginal, or parenteral.
6. (Previously Presented) The method as claimed in claim 1, wherein said administering is subcutaneous, intramuscular, intravenous, or intradermal.
7. (Withdrawn) A method of inducing the expression of β_1 integrin molecules in cancer cells consisting of administering to a patient in need of treatment an effective amount of a composition consisting essentially of an angiotensin, wherein said method induces the expression of β_1 integrin molecules in cancer cells.

14. (Previously Presented) The method as claimed in claim 1, wherein said administering further comprises an excipient or carrier.

15. (Withdrawn) The method as claimed in claim 7, wherein said administering further comprises an excipient or carrier.

16. (Currently Amended) A method of treatment ~~or prevention~~ of metastasis of cancer cells comprising administering to a patient in need of treatment an effective amount of a composition consisting essentially of an angiotensin, wherein said cancer cells are derived from at least one of the group consisting of skin, prostate, bone and cervix, wherein said method treats ~~or prevents~~ metastasis of said cancer cells.

17. (Previously Presented) The method as claimed in claim 16, wherein said administering further comprises an excipient or carrier.

18. (Previously Presented) The method as claimed in claim 16, wherein said angiotensin is angiotensin-II.

19. (Previously Presented) The method as claimed in claim 16, wherein said administering is oral, rectal, nasal, topical, vaginal, or parenteral.

20. (Previously Presented) The method as claimed in claim 16, wherein said administering is subcutaneous, intramuscular, intravenous, or intradermal.

21. (Withdrawn) A method of inducing the expression of β_1 integrin molecules in cancer cells comprising administering to a patient in need of treatment a composition consisting essentially of an effective amount of an angiotensin, wherein said cancer cells are derived from at least one of the group consisting of skin, prostate, bone and cervix, wherein said method induces the expression of β_1 integrin molecules in cancer cells.

22. (Withdrawn) The method as claimed in claim 21, wherein said administering further comprises an excipient or carrier.
23. (Withdrawn) The method as claimed in claim 21, wherein said angiotensin is angiotensin-II.
24. (Withdrawn) The method as claimed in claim 21, wherein said administering is oral, rectal, nasal, topical, vaginal, or parenteral.
25. (Withdrawn) The method as claimed in claim 21, wherein said administering is subcutaneous, intramuscular, intravenous, or intradermal.
26. (New) A method of reducing the invasiveness of cancer cells consisting of administering to a patient in need of treatment an effective amount of a composition consisting essentially of an angiotensin, wherein said method reduces the invasiveness of said cancer cells.
27. (New) The method as claimed in claim 26, wherein said cancer cells are derived from at least one of the group consisting of breast, skin, large bowel, prostate, lung, bone, cervix, stomach and rectum.
28. (New) The method as claimed in claim 26, wherein said angiotensin is angiotensin-II.
29. (New) The method as claimed in claim 26, wherein said administering is oral, rectal, nasal, topical, vaginal, or parenteral.
30. (New) The method as claimed in claim 26, wherein said administering is subcutaneous, intramuscular, intravenous, or intradermal.
31. (New) The method as claimed in claim 26, wherein said composition further comprises an excipient or carrier.

32. (New) A method of reducing the invasiveness of cancer cells comprising administering to a patient in need of treatment an effective amount of a composition consisting essentially of an angiotensin, wherein said cancer cells are derived from at least one of the group consisting of skin, prostate, bone and cervix, wherein said method reduces the invasiveness of said cancer cells.

33. (New) The method as claimed in claim 32, wherein said administering further comprises an excipient or carrier.

34. (New) The method as claimed in claim 32, wherein said angiotensin is angiotensin-II.

35. (New) The method as claimed in claim 32, wherein said administering is oral, rectal, nasal, topical, vaginal, or parenteral.

36. (New) The method as claimed in claim 32, wherein said administering is subcutaneous, intramuscular, intravenous, or intradermal.